Amarin Corp Plc (AMRN)

[sts66]

Lovaza sold $1B+/yr before the FDA declared TGs are not a risk factor for CVD (based on terribly flawed "science") - look at the sales trends for L and GL over the last couple years - dropping like a rock. V is gaining market share, partly through NRx, but also partly because the O3 market is shrinking.